Ignite Creation Date:
2025-12-25 @ 12:08 AM
Ignite Modification Date:
2026-02-01 @ 7:29 AM
Study NCT ID:
NCT04831658
Status:
UNKNOWN
Last Update Posted:
2022-06-02
First Post:
2021-04-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma
Sponsor:
Mingzhi Zhang
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Primary Central Nervous System Lymphoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | BTK inhibitor | View |
| None | PD-1 | View |
| None | fotemustine | View |
| None | CRR | View |
| None | ORR | View |
| None | DCR | View |
| None | PFS | View |
| None | OS | View |
| None | ADR | View |
| None | Adverse events | View |
| None | ECOG score | View |
| None | laboratory examination | View |
| None | vital signs | View |
| None | physical examination | View |
| None | Time to disease progression (TTP) | View |
| None | median survival (MST) | View |
| None | quality of life (QOL) | View |
| None | adverse reactions (ADR) | View |